Fast Five Quiz: KRAS Mutations in Non-Small Cell Lung Cancer

Winston W. Tan, MD


August 17, 2021

Patients with KRAS mutations tend to have a poorer prognosis, and KRAS mutations have been identified as negative prognostic biomarkers. Patients with wild-type KRAS appear to have a shorter survival than those with KRAS mutations. However, KRAS mutational status is not predictive of a lack of chemotherapeutic efficacy.

A 2018 meta-analysis showed that EGFR mutations were significantly associated with improved OS and disease-free survival, whereas KRAS mutations predicted worse disease-free survival and OS in patients with resected NSCLC.

Learn more about the clinical significance of KRAS mutations in NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.